EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
EGRX on OTC
Type / Class
Equity / Common Stock
Shares outstanding
13.1M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
12.4K
Holdings value
$33.3K
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 38.08% 0% $14.3M 4.95M 0% Nantahala Capital Management, LLC 30 Jun 2025
Union Square Park Capital Management, LLC 11.44% $2.91M 1.49M Union Square Park Partners, LP 31 Dec 2024
Nantahala Capital Partners Limited Partnership 6.24% $1.59M 811K NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP 16 Feb 2025
J. Goldman & Co LP 5.1% $1.93M 667K J. Goldman & Co LP 30 Jun 2025

Institutional Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 12.4K $33.3K $2.70 2
2025 Q2 12.4K $35.8K $2.90 2
2025 Q1 12.4K $12.1K -$32.5K $0.98 2
2024 Q4 79K $38.7K -$31.4M $0.50 9
2024 Q3 8.56M $31.9M -$6.51M $3.73 64
2024 Q2 9.91M $55.5M -$2.77M $5.60 74
2024 Q1 10.5M $54.8M +$2.57M $5.24 91
2023 Q4 10M $52.4M -$16.5M $5.23 102
2023 Q3 10.3M $163M -$8.34M $15.77 106
2023 Q2 10.8M $209M -$25.5M $19.44 121
2023 Q1 11.8M $334M +$6.37M $28.37 153
2022 Q4 11.6M $338M +$2.94M $29.23 152
2022 Q3 11.5M $303M -$16.4M $26.42 141
2022 Q2 11.6M $516M +$21.3M $44.43 157
2022 Q1 11.2M $555M -$3.38M $49.49 157
2021 Q4 11.3M $573M -$47.7M $50.92 161
2021 Q3 11.8M $660M -$11.3M $55.78 150
2021 Q2 12M $516M -$4.65M $42.80 139
2021 Q1 12.2M $508M -$2.9M $41.74 149
2020 Q4 12.3M $574M -$7.94M $46.57 159
2020 Q3 12.5M $532M -$18.6M $42.48 166
2020 Q2 13M $623M -$13.1M $47.98 159
2020 Q1 13.3M $611M -$10.3M $46.00 165
2019 Q4 13.2M $795M +$5.7M $60.08 174
2019 Q3 13.2M $746M -$18.8M $56.57 181
2019 Q2 13.5M $752M +$12.9M $55.68 177
2019 Q1 13.4M $675M -$20.1M $50.49 176
2018 Q4 13.9M $561M -$101M $40.29 176
2018 Q3 15.4M $1.07B -$2M $69.33 185
2018 Q2 15.4M $1.16B -$26.7M $75.66 180
2018 Q1 15.8M $832M -$8.77M $52.69 170
2017 Q4 16M $852M +$1.04M $53.42 164
2017 Q3 15.9M $947M +$8.08M $59.64 164
2017 Q2 15.4M $1.21B +$314M $78.89 170
2017 Q1 16.4M $1.36B +$96.1M $82.94 144
2016 Q4 16.5M $1.31B -$54.4M $79.34 147
2016 Q3 16.7M $1.17B +$53.7M $70.00 134
2016 Q2 17.2M $667M +$29.3M $38.79 113
2016 Q1 15.4M $625M -$9.31M $40.50 115
2015 Q4 14.9M $1.32B +$75.9M $88.67 131
2015 Q3 14.1M $1.04B +$47.8M $74.03 117
2015 Q2 13.4M $1.08B +$144M $80.86 119
2015 Q1 11.7M $489M +$142M $41.89 68
2014 Q4 9.2M $143M +$21.8M $15.50 28
2014 Q3 2.97M $37.6M +$13.8M $12.65 24
2014 Q2 1.74M $24.9M -$1.91M $14.33 27
2014 Q1 1.91M $24.4M +$24.4M $12.75 28